Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification

Background Glucagon-like peptide-1 receptor agonist (GLP-1RA), which is a therapeutic agent for the treatment of type 2 diabetes mellitus, has a beneficial effect on the cardiovascular system. Methods To examine the protective effects of GLP-1RAs on proliferation and migration of vascular smooth muscle cells (VSMCs), A-10 cells exposed to angiotensin II (Ang II) were treated with either exendin-4, liraglutide, or dulaglutide. To examine the effects of GLP-1RAs on vascular calcification, cells exposed to high concentration of inorganic phosphate (Pi) were treated with exendin-4, liraglutide, or dulaglutide. Results Ang II increased proliferation and migration of VSMCs, gene expression levels of Ang II receptors AT1 and AT2, proliferation marker of proliferation Ki-67 (Mki-67), proliferating cell nuclear antigen (Pcna), and cyclin D1 (Ccnd1), and the protein expression levels of phospho-extracellular signal-regulated kinase (p-Erk), phospho-c-JUN N-terminal kinase (p-JNK), and phospho-phosphatidylinositol 3-kinase (p-Pi3k). Exendin-4, liraglutide, and dulaglutide significantly decreased the proliferation and migration of VSMCs, the gene expression levels of Pcna, and the protein expression levels of p-Erk and p-JNK in the Ang II-treated VSMCs. Erk inhibitor PD98059 and JNK inhibitor SP600125 decreased the protein expression levels of Pcna and Ccnd1 and proliferation of VSMCs. Inhibition of GLP-1R by siRNA reversed the reduction of the protein expression levels of p-Erk and p-JNK by exendin-4, liraglutide, and dulaglutide in the Ang II-treated VSMCs. Moreover, GLP-1 (9-36) amide also decreased the proliferation and migration of the Ang II-treated VSMCs. In addition, these GLP-1RAs decreased calcium deposition by inhibiting activating transcription factor 4 (Atf4) in Pi-treated VSMCs. Conclusion These data show that GLP-1RAs ameliorate aberrant proliferation and migration in VSMCs through both GLP-1R-dependent and independent pathways and inhibit Pi-induced vascular calcification.

[1]  E. Rhee Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone? , 2022, Endocrinology and metabolism.

[2]  D. Giugliano,et al.  GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs , 2021, Cardiovascular Diabetology.

[3]  R. Loomba,et al.  The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk , 2021, Current Diabetes Reports.

[4]  S. E. Park,et al.  Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling. , 2020, Biochemical and biophysical research communications.

[5]  Xinfeng Liu,et al.  Calcification in Atherosclerotic Plaque Vulnerability: Friend or Foe? , 2020, Frontiers in Physiology.

[6]  M. Gilbert,et al.  An overview of GLP-1 agonists and recent cardiovascular outcomes trials , 2019, Postgraduate Medical Journal.

[7]  Jiao Zhang,et al.  Angiotensin II Receptor Type 1 Antagonists Modulate Vascular Smooth Muscle Cell Proliferation and Migration via AMPK/mTOR , 2019, Cardiology.

[8]  S. Surani,et al.  Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence , 2019, World journal of diabetes.

[9]  S. Allahverdian,et al.  Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (Apolipoprotein E)-Deficient Mouse Atherosclerosis , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[10]  J. Marrs,et al.  Antihyperglycemic Medications and Cardiovascular Risk Reduction , 2017, European endocrinology.

[11]  K. Miyauchi,et al.  Coronary Artery Disease and Type 2 Diabetes Mellitus. , 2017, International heart journal.

[12]  Qinghua Wang,et al.  Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies , 2017, Front. Physiol..

[13]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[14]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[15]  M. Bennett,et al.  Vascular Smooth Muscle Cells in Atherosclerosis. , 2016, Circulation research.

[16]  J. Essers,et al.  The renin-angiotensin system and its involvement in vascular disease. , 2015, European journal of pharmacology.

[17]  Wei Jiang,et al.  Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways , 2015, Cardiovascular Diabetology.

[18]  A. Orekhov,et al.  Mechanisms of medial arterial calcification in diabetes. , 2014, Current pharmaceutical design.

[19]  A. Sposito,et al.  Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists , 2014, Cardiovascular Diabetology.

[20]  C. St. Hilaire,et al.  Medial vascular calcification revisited: review and perspectives. , 2014, European heart journal.

[21]  T. Jin,et al.  GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro. , 2013, American journal of physiology. Endocrinology and metabolism.

[22]  L. Havekes,et al.  Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. , 2013, Atherosclerosis.

[23]  M. Festing,et al.  Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1 , 2010, Thrombosis and Haemostasis.

[24]  E. Tomás,et al.  Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis , 2010, Trends in Endocrinology & Metabolism.

[25]  T. Engstrøm,et al.  Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart , 2008, Regulatory Peptides.

[26]  J. Holst,et al.  The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. , 2006, American journal of physiology. Endocrinology and metabolism.

[27]  A. Van der Laarse,et al.  Vascular smooth muscle cells and calcification in atherosclerosis. , 2004, American heart journal.

[28]  C. Shanahan,et al.  Biology of Calcification in Vascular Cells: Intima versus Media , 2001, Herz.

[29]  L. B. Knudsen,et al.  Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. , 1996, European journal of pharmacology.

[30]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[31]  M. Bennett,et al.  Vascular smooth muscle cells in atherosclerosis: time for a re-assessment , 2021 .

[32]  H. Vaudry,et al.  How does angiotensin AT 2 receptor activation help neuronal differentiation and improve neuronal pathological situations , 2012 .

[33]  Lubo Zhang,et al.  Angiotensin II receptors and drug discovery in cardiovascular disease. , 2011, Drug discovery today.

[34]  B. L. Metcalfe DEFINING THE ROLE OF THE ANGIOTENSIN II TYPE 2 RECEPTOR IN CARDIOVASCULAR DISEASE , 2004 .